Exhibit 10.1

SECURITIES PURCHASE AGREEMENT

This Securities Purchase Agreement (this “Agreement”) is made as of January 10,
2007 between FermaVir Pharmaceuticals, Inc., a Florida corporation (the
“Company”), and the investors listed on Exhibit A hereto, each of which is
herein referred to as an “Investor” and collectively, the “Investors”.

RECITALS:

WHEREAS, the Investors desire to purchase from the Company, and the Company
desires to sell to the Investors, up to approximately 1,733,333 shares of the
Company’s common stock, par value $0.0001 per share (the “Common Stock”) and up
to approximately 3,466,667 warrants to purchase shares of the Common Stock (the
“Warrants”), upon the terms and subject to the conditions set forth herein;

NOW, THEREFORE, in consideration of the premises and mutual covenants contained
herein, the parties hereto agree as follows:

1.             PURCHASE AND SALE OF SECURITIES.

1.1          Purchase and Sale of Securities.  Upon the terms and subject to the
conditions of this Agreement, at the Closing (as defined below), the Company
agrees to sell to the Investors, and each Investor agrees to purchase from the
Company the number of shares of the Company’s Common Stock and Warrants set
forth opposite such Investor’s name on Exhibit A hereto (collectively, the
“Securities”) at the per share purchase price of $0.75 (“Purchase Price”).  The
Warrants shall be exercisable at $1.00 per share for a period of 10 years from
the date of issuance.

1.2          Closing.  The closing of the purchase and sale of the Securities
(the “Closing”) shall take place at the offices of the Company at 5:00 p.m.,
Eastern time on January 10, 2007, or such other location, time or date as the
parties shall mutually agree, but only after the satisfaction or waiver of each
of the conditions set forth in Sections 6 and 7 (the “Closing Date”).

1.3          Deliveries.  At the Closing, the Company shall deliver to each
Investor at the address set forth on such Investor’s signature page hereto, a
certificate or certificates, registered in the name of the applicable Investor,
representing the shares of Common Stock and Warrants purchased by such Investor,
and each Investor shall deliver to the Company the aggregate Purchase Price, by
wire transfer of immediately available funds to the following account:

HSBC Bank USA

950 Third Avenue

New York, NY 10022

A/C of Sichenzia Ross Friedman Ference LLP, IOLA

A/C#

1

--------------------------------------------------------------------------------

ABA#

REMARK:  FERMAVIR

2.                                       REPRESENTATIONS AND WARRANTIES OF THE
COMPANY.

For purposes of this Section, all references to “Company” in Sections 2.1, 2.4
(with the exception of subsection (a) thereof), 2.7, 2.9 through 2.12, and 2.14
through 2.20 shall be deemed to be a reference to the Company and all of its
direct and indirect subsidiaries.  The Company hereby represents and warrants to
each Investor that, except as set forth on a Schedule of Exceptions (the
“Company Schedule of Exceptions”) attached hereto as Schedule A, which
exceptions shall be deemed to be representations and warranties as if made
hereunder:

2.1           Corporate Organization.  The Company is a corporation duly
organized, validly existing and in good standing under the laws of its state of
incorporation, and has the requisite corporate power and authority to own or
lease its properties and to carry on its business as now being conducted.  The
Company is duly qualified as a foreign corporation to do business and is in good
standing in every jurisdiction in which the property owned or leased by it or
the nature of the business conducted by it makes such qualification necessary,
except to the extent that the failure to be so qualified or in good standing
would not have, individually or in the aggregate, a Material Adverse Effect. 
For purposes of this Agreement, “Material Adverse Effect” shall mean, as to any
entity, any material adverse effect on the business, operations, conditions
(financial or otherwise), assets or results of operations of that entity
individually or of the Company and its subsidiaries as a whole.

2.2           Capitalization; Organizational Documents.

(a)           The authorized capital stock of the Company will consist
immediately prior to the Closing of 100,000,000 shares of Common Stock, of which
as of the date hereof, 19,193,231 shares are issued and outstanding, and
20,000,000 shares of preferred stock of the Company, of which, as of the date
hereof, no shares of preferred stock are issued and outstanding.  All of the
issued and outstanding shares have been duly and validly issued and are fully
paid and nonassessable and have been issued in accordance with all applicable
federal and state securities laws.  No shares of Common Stock are subject to
preemptive rights or any other similar rights or any liens suffered or permitted
by the Company.  There are no preemptive rights or rights of first refusal or
similar rights which are binding on the Company permitting any person to
subscribe for or purchase from the Company shares of its capital stock pursuant
to any provision of applicable law, the Articles of Incorporation (as defined
below) or the Company’s By-laws.  There are no securities or instruments
containing anti-dilution or similar provisions that will be triggered by the
issuance of the Securities.  The Company has made available to each Investor
true and correct copies of the Company’s Articles of Incorporation, as amended
and as in effect on the date hereof (the “Articles of Incorporation”), and the
Company’s By-laws, as in effect on the date hereof (the “By-laws”).

(b)           Upon issuance of the Securities and payment of the Purchase Price
therefor in accordance with the terms of this Agreement, the Securities will be
duly authorized, validly issued, fully paid and nonassessable, and free and
clear of any restrictions on transfer and any taxes, claims, liens, pledges,
options, security interests, purchase rights, preemptive rights,

2

--------------------------------------------------------------------------------

trusts, encumbrances or other rights or interests of any other person (other
than any restrictions under the Securities Act of 1933, as amended (the
“Securities Act”).

2.3           Authorization; Enforcement.  (a) The Company has the requisite
corporate power and authority to enter into and perform its obligations under
this Agreement and to issue, sell and perform its obligations with respect to
the Securities in accordance with the terms hereof, (b) the execution and
delivery of this Agreement by the Company and the consummation by it of the
transactions contemplated hereby have been duly authorized by the Company’s
Board of Directors and its stockholders and no further consent or authorization
is required by the Company, its Board of Directors or its stockholders, except
as disclosed on the Company Schedule of Exceptions and (c) this Agreement has
been duly executed and delivered by the Company.  This Agreement, when executed
and delivered by the Company, constitutes a valid and binding obligation of the
Company enforceable against the Company in accordance with its terms, except as
such enforceability may be limited by general principles of equity or applicable
bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws
relating to, or affecting generally, the enforcement of creditors’ rights and
remedies.

2.4           No Conflicts.  The execution, delivery and performance of this
Agreement by the Company, and the consummation by the Company of the
transactions contemplated hereby, will not (a) result in a violation of the
Articles of Incorporation or By-laws of the Company, or (b) violate or conflict
with, or result in a breach of, any provision of, or constitute a default (or an
event which with notice or lapse of time or both would become a default) under,
or give to others any rights of termination, amendment, acceleration or
cancellation of, or result in the creation of any lien on or against any of the
material properties of the Company, any material note, bond, mortgage,
agreement, license, indenture or instrument to which the Company is a party, or
result in a violation of any statute, law, rule, regulation, writ, injunction,
order, judgment or decree applicable to the Company or by which any property or
asset of the Company is bound or affected, except where such violation,
conflict, breach or other consequence would not have a Material Adverse
Effect.   Except as specifically contemplated by this Agreement and applicable
blue sky laws, the Company is not required to obtain any consent, authorization
or order of, or make any filing or registration with, any court or governmental
or regulatory or self-regulatory agency in order for it to execute, deliver or
perform any of its obligations under or contemplated by this Agreement in
accordance with the terms hereof.  All consents, authorizations, orders, filings
and registrations that the Company is required to obtain pursuant to the
preceding sentence have been obtained or effected on or prior to the date
hereof, except for those required pursuant to blue sky laws.

2.5           SEC Documents; Financial Statements.  The Company has filed all
reports, schedules, forms, statements and other documents required to be filed
by it with the Securities and Exchange Commission (the “SEC”) pursuant to the
reporting requirements of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”) (all of the foregoing, and all other documents and registration
statements heretofore filed by the Company with the SEC being hereinafter
referred to as the “SEC Documents”).  The Common Stock is currently traded on
the Over the Counter Bulletin Board.  The Company has delivered or made
available to each Investor true and complete copies of the SEC Documents.  As of
their respective dates, the SEC Documents complied in all material respects with
the requirements of the Securities Act, and the Exchange Act and the rules and
regulations of the SEC promulgated thereunder applicable to the

3

--------------------------------------------------------------------------------

SEC Documents, and none of the SEC Documents, at the time they were filed with
the SEC (except those SEC Documents that were subsequently amended), contained
any untrue statement of a material fact or omitted to state a material fact
required to be stated therein or necessary in order to make the statements
therein, in light of the circumstances under which they were made, not
misleading.  Except as disclosed in the Company Schedule of Exceptions, as of
their respective dates, the financial statements of the Company and its
subsidiaries included (or incorporated by reference) in the SEC Documents
complied as to form in all material respects with applicable accounting
requirements and the published rules and regulations of the SEC or other
applicable rules and regulations with respect thereto.  Such financial
statements have been prepared in accordance with generally accepted accounting
principles applied on a consistent basis during the periods involved (except (a)
as may be otherwise indicated in such financial statements or the notes thereto,
or (b) in the case of unaudited interim statements, to the extent they may
exclude footnotes or may be condensed or summary statements) and fairly present
the financial position of the Company and its subsidiaries as of the dates
thereof and the results of its operations and cash flows for the periods then
ended (subject, in the case of unaudited statements, to normal year-end audit
adjustments).

2.6           Securities Law Exemption.  Assuming the truth and accuracy of each
Investor’s representations set forth in this Agreement, the offer, sale and
issuance of the Securities as contemplated by this Agreement are exempt from the
registration requirements of the Securities Act and applicable state securities
laws, and neither the Company nor any authorized agent acting on its behalf has
taken or will take any action hereafter that would cause the loss of such
exemption.

2.7           Litigation.  All actions, suits, arbitrations or other proceedings
or, to the Company’s knowledge, investigations pending or threatened against the
Company that would have a Material Adverse Effect on the Company, are disclosed
in the SEC Documents.  There is no action, suit, proceeding or, to the Company’s
knowledge, investigation that questions this Agreement or the right of the
Company to execute, deliver and perform under same.

2.8           Use of Proceeds.  The net proceeds from the sale of the Securities
shall be used solely for general corporate and working capital purposes.

2.9           Intellectual Property.  The Company owns, or has the contractual
right to use, sell or license all intellectual property necessary or required
for the conduct of its business as presently conducted and as proposed to be
conducted, including, without limitation, all trade secrets, processes, source
code, licenses, trademarks, service marks, trade names, logos, brands,
copyrights, patents, franchises, domain names and permits.  The Company has not
received any communications alleging that the Company has violated or, by
conducting its business presently conducted violates or will violate any
intellectual property rights of any other person or entity.

2.10         Title to Property and Assets.  The Company has good and marketable
title to or, in the case of leases and licenses, has valid and subsisting
leasehold interests or licenses in, all of its properties and assets (whether
real or personal, tangible or intangible) free and clear of any liens or other
encumbrances, except for liens or other encumbrances that do not, individually
or in the aggregate, have a Material Adverse Effect.  With respect to property
leased by the Company, the Company has a valid leasehold interest in such
property pursuant to leases which

4

--------------------------------------------------------------------------------

are in full force and effect, and the Company is in compliance in all material
respects with the provisions of such leases.

2.11         Compliance with Laws.  The Company is in compliance with all laws,
rules, regulations, orders, judgments or decrees that are applicable to the
Company, the conduct of its business as presently conducted, and the ownership
of its property and assets (including, without limitation, all Environmental
Laws (as defined below) and laws related to occupational safety, health, wage
and hour, and employment discrimination).  All required reports and filings with
governmental authorities have been properly made as and when required, except
where the failure to report or file would not, individually or in the aggregate,
have a Material Adverse Effect.  “Environmental Laws” means all federal, state,
local and foreign laws, ordinances, treaties, rules, regulations, guidelines and
permit conditions relating to contamination or pollution of the environment
(including ambient air, surface water, ground water, land surface or subsurface
strata) or the protection of human health and worker safety, including, without
limitation, laws and regulations relating to transportation, storage, use,
manufacture, disposal or release of, or exposure of employees or others to,
Hazardous Materials (as defined below) or emissions, discharges, releases or
threatened releases of Hazardous Materials.  “Hazardous Materials” means any
substance that has been designated by any governmental entity or by applicable
Environmental Laws to be radioactive, toxic, hazardous or otherwise a danger to
health or the environment, including, without limitation, PCBs, asbestos,
petroleum, urea formaldehyde and all substances listed as hazardous substances
pursuant to the Comprehensive Environmental Response, Compensation, and
Liability Act of 1980, as amended, or defined as a hazardous waste pursuant to
the Resource Conservation and Recovery Act of 1976, as amended, and the
regulations promulgated pursuant to Environmental Laws, but excluding office and
janitorial supplies maintained in accordance with Environmental Laws.

2.12         Licenses and Permits.  The Company has obtained and maintains all
material federal, state, local and foreign licenses, permits, consents,
approvals, registrations, memberships, authorizations and qualifications
required to be maintained in connection with the operations of the Company as
presently conducted, the lack of which could have a Material Adverse Effect. 
The Company is not in default in any material respect under any of such
licenses, permits, consents, approvals, registrations, memberships,
authorizations and qualifications.

2.13         Related Entities.  Except for the Subsidiaries set forth on the
Company Schedule of Exceptions, the Company does not presently own or control,
directly or indirectly, any interest in any other subsidiary, corporation,
association or other business entity.  The Company is not a party to any joint
venture, partnership or similar arrangement.

2.14         Changes.  Except as disclosed on the Company Schedule of Exceptions
and in the SEC Documents, since July 31, 2006, the Company has operated its
business diligently and in the ordinary course of business and, to the knowledge
of the Company, there has not been, or the Company has not (as the case may be):

(a)           any Material Adverse Effect;

5

--------------------------------------------------------------------------------

(b)           any damage, destruction or loss, whether or not covered by
insurance, which would have a Material Adverse Effect;

(c)           any waiver or compromise by the Company of a valuable right or of
a material debt owed it;

(d)           sold, encumbered, assigned or transferred any material assets or
properties of the Company, other than in the ordinary course of business;

(e)           incurred any liability, whether accrued, absolute, contingent or
otherwise, and whether due or to become due, other than (i) in the ordinary
course of business or (ii) liabilities that are not, individually or in the
aggregate, material to the business, operations, condition (financial or
otherwise), assets or results of operations of the Company;

(f)            created, incurred, assumed or guaranteed any indebtedness or
subjected any of its assets to any lien or encumbrance, except for indebtedness,
liens or encumbrances that are not, individually or in the aggregate, material
to the business, operations, condition (financial or otherwise), assets or
results of operations of the Company;

(g)           directly or indirectly redeemed, purchased or otherwise acquired
any shares of capital stock of the Company;

(h)           declared, set aside or paid any dividends or made any other
distributions in cash or property on the Company’s capital stock;

(i)            except in the ordinary course of business of the Company,
materially increased the compensation payable or to become payable by the
Company to any of its officers, employees or directors or materially increased
any bonus, insurance, pension or other employee benefit plan, payment or
arrangement made by the Company for or with any such officers, employees or
directors;

(j)            made any direct or indirect loan to any stockholder, employee,
officer or director of the Company, other than advances made in the ordinary
course of business;

(k)           changed any agreement to which the Company is a party which would
have a Material Adverse Effect; or

(l)            entered into any agreement or commitment to do any of the things
described in this Section 2.14.

2.15         Employee Benefit Plans.  All “employee benefit plans,” as such term
is defined in the Employee Retirement Income Security Act of 1974, as amended
(“ERISA”), to which the Company has any liability or obligation, contingent or
otherwise, comply in all material respects and have been maintained and
administered in material compliance with

6

--------------------------------------------------------------------------------

ERISA, the Internal Revenue Code of 1986, as amended (the “Code”), and all other
statutes, orders and governmental rules and regulations applicable to such
employee benefit plans.

2.16         Insurance.  The Company has in full force and effect fire, casualty
and liability insurance policies sufficient in amount (subject to reasonable
deductibles) to allow the Company to replace any of its properties that might be
damaged or destroyed to the extent and in the manner customary for companies in
similar business similarly situated.

2.17         Employees.  The Company does not have any collective bargaining
agreements with any of its employees.  There is no labor union organizing
activity pending or, to the Company’s knowledge, threatened with respect to the
Company.

2.18         Material Contracts.  All contracts, agreements, instruments,
leases, licenses, arrangements, understandings or other documents filed with or
required to be filed as exhibits to the SEC Documents to which the Company
therein is a party or by which it may be bound have been so filed (the “Material
Contracts”).  The Material Contracts that have been filed as exhibits are
complete and correct copies of the contracts, agreements, instruments, leases,
licenses, arrangement, understanding or other documents of which they purport to
be copies.  The Material Contracts are valid and in full force and effect as to
the Company, and, to the Company’s knowledge, to the other parties thereto.

2.21         Brokers and Finders.  Except as disclosed in the Schedule of
Exceptions, the Company has not employed any broker, finder, consultant or
intermediary in connection with the transactions contemplated by this Agreement
that would be entitled to a broker’s, finder’s or similar fee or commission in
connection herewith and therewith.

2.22         Disclosure.  This Agreement, Schedules and Exhibits hereto and all
other documents delivered to the Investors in connection herewith or therewith
at the Closing, do not contain any untrue statement of a material fact, or omit
to state a material fact necessary to make the statements therein, in light of
the circumstances under which they were made, not misleading.  There are no
facts that, individually or in the aggregate, would have a Material Adverse
Effect that have not been disclosed to each Investor in this Agreement
(including the Schedules and Exhibits hereto), the SEC Documents or any other
documents delivered to each Investor in connection herewith or therewith at the
Closing.

3.             REPRESENTATIONS AND WARRANTIES OF INVESTOR.

Each of the Investors, severally and not jointly, hereby represents and warrants
to the Company as to itself and not as to any other Investor, that:

3.1           Organization.  The Investor represents and warrants to, and
covenants with, the Company that the Investor has full right, power, authority
and capacity to enter into this Agreement and to consummate the transactions
contemplated hereby.

3.2           Authorization; Enforcement.  (a) The Investor has the requisite
power and authority to enter into and perform its obligations under this
Agreement, (b) the execution and delivery of this Agreement by the Investor and
the consummation by it of the transactions contemplated hereby have been duly
authorized by all necessary corporate action on the part of

7

--------------------------------------------------------------------------------

the Investor, and (c) this Agreement has been duly executed and delivered by the
Investor.  To the knowledge of the Investor, no other proceedings on the part of
the Investor are necessary to approve and authorize the execution and delivery
of this Agreement.  This Agreement, when executed and delivered, constitutes a
valid and binding obligation of the Investor, enforceable against the Investor
in accordance with its terms, except as such enforceability may be limited by
general principles of equity or applicable bankruptcy, insolvency,
reorganization, moratorium, liquidation or similar laws relating to, or
affecting generally, the enforcement of creditors’ rights and remedies.

3.3           No Conflicts.  The execution, delivery and performance of this
Agreement by the Investor, and the consummation by the Investor of the
transactions contemplated hereby will not (a) result in a violation of the
organizational documents of the Investor, or (b) result in a violation of any
statute, law, rule, regulation, writ, injunction, order, judgment or decree
applicable to the Investor, except where such violation, conflict, breach or
other consequence would not have a Material Adverse Effect.  The Investor is not
required to obtain any consent, authorization or order of, or make any filing or
registration with, any court or governmental or regulatory or self-regulatory
agency in order for it to execute, deliver or perform any of its obligations
under or contemplated by this Agreement in accordance with the terms hereof.

3.4           Investment Representations.

(a)           The Investor is an “accredited investor”, as defined in Regulation
D promulgated under the Securities Act, and has such knowledge, sophistication
and experience in financial and business matters that the Investor is capable of
evaluating the merits and risks of the investment in the Securities.

(b)           The Investor (i) has adequate means of providing for its current
financial needs and possible contingencies, and has no need for liquidity of
investment in the Company, (ii) can afford to hold unregistered Securities for
an indefinite period of time and sustain a complete loss of the entire amount of
the subscription, and (iii) has not made an overall commitment to investments
which are not readily marketable that is so disproportionate as to cause such
overall commitment to become excessive.

(c)           The Investor agrees and understands that the Securities are being
offered and sold to the Investor in reliance upon specific exemptions from the
registration requirements of the Securities Act and the rules and regulations
promulgated thereunder and that, in order to determine the availability of such
exemptions and the eligibility of the Investor to acquire the Securities, the
Company is relying upon the truth and accuracy of the Investor’s representations
and warranties, and compliance with the Investor’s covenants and agreements, set
forth in this Agreement.  The Investor further agrees with the Company that (i)
no Securities were offered or sold to the Investor by means of any form of
general solicitation or general advertising, and in connection therewith, the
Investor did not (1) receive or review any advertisement, article, notice or
other communication published in a newspaper or magazine or similar media or
broadcast over television or radio, whether closed circuit or generally
available; or (2) attend any seminar meeting or industry investor conference
whose attendees were invited by any general solicitation or general
advertising.  The Investor hereby acknowledges that the offering of the
Securities has not been reviewed by the SEC or any state regulatory authority

8

--------------------------------------------------------------------------------

since the offering of the Securities is intended to be exempt from the
registration requirements of Section 5 of the Securities Act pursuant to
Regulation D  promulgated thereunder.  The Investor understands that the
Securities have not been registered under the Securities Act and agrees not to
sell or otherwise transfer the Securities unless they are registered under the
Securities Act or unless an exemption from such registration is available.

(d)           The Investor has had access to the Company’s SEC Documents and
other public filings.

(e)           With respect to corporate tax and other economic considerations
involved in an investment in the Securities, the Investor is not relying on the
Company.  The Investor has carefully considered and has, to the extent the
Investor believes such discussion necessary, discussed with its professional
legal, tax, accounting and financial advisors the suitability of an investment
in the Securities for its particular tax and financial situation and has
determined that the Securities are a suitable investment for the Investor.

(f)            The Company has made available to the Investor all documents and
information that the Investor has requested relating to an investment in the
Securities.

(g)           Subject to the Company’s disclosures in this Agreement and the SEC
Documents, the Investor recognizes that the Company has generated no revenues to
date, is not expected to have any products commercially available for a number
of years, if at all, and that investment in the Company involves substantial
risks, including loss of the entire amount of such investment and has taken full
cognizance of and understands all of the risk factors relating to the purchase
of the Securities.

(h)           The Investor has not been formed for the specific purpose of
acquiring the Securities.

4.             COVENANTS.

4.1           Confidentiality.  Each Investor hereby acknowledges that
unauthorized disclosure of information regarding the offering of the Securities
pursuant to this Agreement may cause the Company to violate Regulation FD and
each Investor agrees to keep such information confidential. The Company shall
not publicly disclose the name of any Investor, or include the name of any
Investor in any filing with the Commission or any regulatory agency or trading
market, without the prior written consent of such Investor, except (i) as
required by the federal securities laws and in connection with the registration
statement contemplated by this Agreement and (ii) to the extent such disclosure
is required by law or trading market regulations.

4.2           Restrictions on Transfer.

(a)           Each Investor hereby agrees, severally and not jointly, that,
except in accordance with a registration statement filed pursuant to Section 5.2
of this Agreement, it will not dispose of any of such Investor’s Securities
(other than pursuant to Rule 144 promulgated under the Securities Act (“Rule
144”) or pursuant to a registration statement filed with the SEC pursuant to the
Securities Act) unless and until such Investor shall have (A) notified the
Company of the proposed disposition and shall have furnished the Company

9

--------------------------------------------------------------------------------

with a statement of the circumstances surrounding the proposed disposition and
(B) if requested by the Company, furnished the Company with an opinion of
counsel, reasonably satisfactory in form and substance to the Company and the
Company’s counsel, to the effect that such disposition will not require
registration under the Securities Act.  The restrictions on transfer imposed by
this Section 4.2 shall cease and terminate as to the Securities held by an
Investor when:  (x) such Securities shall have been effectively registered under
the Securities Act and sold by the holder thereof in accordance with such
registration, or (y) on delivery of an opinion of the kind described in the
preceding sentence with respect to such Securities.  Each certificate evidencing
the Securities shall bear an appropriate restrictive legend as set forth in
Section 4.2(b), except that such legend shall not be required after a transfer
is made in compliance with Rule 144 or pursuant to a registration statement or
if the opinion of counsel referred to above is issued and provides that such
legend is not required in order to establish compliance with any provisions of
the Securities Act.  The Company agrees that pursuant to the prior sentence, it
will, no later than five Business Days (“Business Day” shall mean any day banks
are open for business in New York, New York) following (a) receipt by the
Company’s transfer agent of a certificate representing Securities issued with a
restrictive legend, accompanied by a certification of the Investor in form
suitable for processing by the Company that a prospectus has been delivered (in
the case of sale pursuant to prospectus, a “Prospectus Letter”) or customary
supporting documentation, including legal opinion if required pursuant to Clause
(B) above, “Supporting Documentation”) and (b) receipt by the Company of notice
of such delivery to the transfer agent and Prospectus Letter or Supporting
Documentation, as the case may be (such notice to be sent by facsimile to the
attention of the Company’s president and CEO at the fax number set forth in
Section 8.6 hereof) deliver or cause to be delivered (evidence of deposit for
next day delivery with a nationally recognized overnight delivery service shall
be deemed delivery) to such Investor a certificate representing such Securities
that is free from all restrictive and other legends.  The Company may not make
any notation on its records or give instructions to any transfer agent of the
Company that enlarge the restrictions on transfer set forth in this Section.  In
the event the Prospectus Letter or Supporting Documentation is not in form
suitable for processing by to the Company, the five Business Days shall toll
until the Company receives a Prospectus Letter or Supporting Documentation that
is in form suitable for processing.

(b)           Notwithstanding the provisions of Section 4.2(a), no registration
statement or opinion of counsel shall be necessary for a transfer by an Investor
of the Securities to a subsidiary, member, partner, stockholder or affiliate of
that Investor, if the transferee agrees in writing to be subject to the terms
hereof to the same extent as if such transferee were an Investor hereunder.

(c)           It is understood that, subject to Sections 4.2(a) and 4.2(b), the
certificates evidencing the Securities will bear the following legends:

(i)            THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES
ACT OF 1933 (THE “SECURITIES ACT”) OR UNDER APPLICABLE STATE SECURITIES LAWS AND
MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER
THE SECURITIES ACT AND ANY APPLICABLE STATE SECURITIES LAWS OR PURSUANT TO
AVAILABLE EXEMPTIONS FROM SUCH REGISTRATION, PROVIDED THAT THE SELLER DELIVERS
TO THE COMPANY AN OPINION OF COUNSEL (WHICH OPINION IS

10

--------------------------------------------------------------------------------

REASONABLY SATISFACTORY TO THE COMPANY) CONFIRMING THE AVAILABILITY OF SUCH
EXEMPTION.

(ii)           Any legend required by the laws of any other applicable
jurisdiction.

4.3           Securities Compliance.  The Company shall take all action
necessary to comply with any federal or state securities laws applicable to the
transactions contemplated hereunder.

5.             REGISTRATION RIGHTS.

5.1           Registrable Shares.  As used herein the term “Registrable
Security” means (a) each of the Shares, (b) the shares of Common Stock of the
Company issuable upon exercise of the Warrants and (c) any Common Stock of the
Company issued as (or issuable on the conversion or exercise of any warrant,
right or other security that is issued as) a dividend or other distribution with
respect to, or in exchange for, or in replacement of, the shares referenced in
clause (a) above; provided, however, that with respect to any particular
Registrable Security held by an Investor, such security shall cease to be a
Registrable Security when, as of the date of determination, (a) it has been
effectively registered under the Securities Act and disposed of pursuant
thereto, or (b) registration under the Securities Act is no longer required for
the immediate public distribution of any particular Registrable Shares held by
that Investor and its affiliates.  In the event of any merger, reorganization,
consolidation, recapitalization or other change in corporate structure affecting
the Common Stock, such adjustment shall be made in the definition of
“Registrable Security” as is appropriate in order to prevent any dilution or
enlargement of the rights granted pursuant to this Section 5.

5.2           Mandatory Registration.

(a)           On or before 90 days following the Closing Date, the Company shall
prepare and file with the Commission the Registration Statement covering the
resale of all of the Registrable Shares for an offering to be made on a
continuous basis pursuant to Rule 415 (the “Required Filing Date”).  The
Registration Statement required hereunder shall be on Form SB-2 (except if the
Company is not then eligible to register for resale the Registrable Shares on
Form SB-2, in which case the Registration Statement shall be on another
appropriate form in accordance herewith).  The Company shall use its
commercially reasonable efforts to cause the Registration Statement to be
declared effective under the Securities Act as promptly as possible after the
filing thereof, but in any event not later than the 120th day after the Closing
Date, if no review by the SEC or the 150th day if reviewed by the SEC (the
“Effectiveness Date”), and shall use its commercially reasonable efforts to keep
the Registration Statement continuously effective under the Securities Act until
the earlier of the date when all Registrable Shares covered by the Registration
Statement (a) have been sold pursuant to the Registration Statement or an
exemption from the registration requirements of the Securities Act or (b) may be
sold without volume restrictions pursuant to Rule 144(k) as determined by the
counsel to the Company pursuant to a written opinion letter to such effect,
addressed and acceptable to the Company’s transfer agent and the affected
Investors or (c) the second anniversary of the date on which the

11

--------------------------------------------------------------------------------

Registration Statement is declared effective (the “Effectiveness Period”) or
such longer time as the Company may determine.

(b)  If: (i) the Registration Statement is not filed on or prior to its Required
Filing Date or (ii) the Company fails to file with the Commission a request for
acceleration in accordance with Rule 461 promulgated under the Securities Act,
within five business days of the date that the Company is notified (orally or in
writing, whichever is earlier) by the Commission that a Registration Statement
will not be “reviewed”, or not subject to further review, or (iii) a
Registration Statement filed or required to be filed hereunder is not declared
effective by the Commission on or before the required Effectiveness Date, or
(iv) after a Registration Statement is first declared effective by the
Commission, it ceases for any reason to remain continuously effective as to all
Registrable Securities for which it is required to be effective, or the
Investors are not permitted to utilize the Prospectus therein to resell such
Registrable Securities, for in any such cases 75 business days (which need not
be consecutive days) in the aggregate during any 12-month period (any such
failure or breach being referred to as an “Event”) and for purposes of clause
(i) or (iii) the date on which such Event occurs, or for purposes of clause (ii)
the date on which such five business day period is exceeded, or for purposes of
clause (iv) the date on which such 75 business day period is exceeded, being
referred to as “Event Date”, then in addition to any other rights the Investors
may have hereunder or under applicable law the Company shall pay to each
Investor an amount in cash, as liquidated damages and not as a penalty, equal to
1% of the aggregate purchase price paid by such Investor pursuant to this
Agreement for any Registrable Securities then held by such Investor on each
monthly anniversary of each such Event Date (if the applicable Event shall not
have been cured by such date) until the applicable Event is cured.  The
liquidated damages pursuant to the terms hereof shall apply on a pro-rata basis
for any portion of a month prior to the cure of an Event and shall not exceed an
aggregate of 8% of the aggregate purchase price paid by the Investors pursuant
to this Agreement.

(c)           Notwithstanding the foregoing, if the Company shall furnish to the
Investors a certificate signed by the Chief Executive Officer of the Company
stating that in the good faith judgment of the Board of Directors of the Company
it would not be in the best interest of the Company for such registration
statement to be filed, the Company shall have the right to defer taking such
action with respect to such filing for a period of not more than seventy-five
(75) days after the date of such certificate; provided, however, that the
Company shall not defer its obligation in this manner more than once in any
twelve (12) month period.

(d)           In the event, the Investor fails to provide the Company with any
information that is required to be provided in the Registration Statement with
respect to such Investor pursuant to Section 5.3(k) within ten (10) days of
receiving a request for such information from the Company, the Company shall
send an additional request to the Investor (the “Additional Request”) and in the
event the Investor fails to respond to the Company within five (5) days of
receipt of the Additional Request, the Company shall be entitled to exclude such
Investor’s Registrable Shares from the Registration Statement.

12

--------------------------------------------------------------------------------

5.3           Covenants of the Company With Respect to Registration.

The Company covenants and agrees as follows:

(A)           NOT LESS THAN FIVE BUSINESS DAYS PRIOR TO THE FILING OF THE
REGISTRATION STATEMENT OR ANY RELATED PROSPECTUS OR ANY AMENDMENT OR SUPPLEMENT
THERETO, FURNISH TO THE INVESTORS COPIES OF ALL SUCH DOCUMENTS PROPOSED TO BE
FILED (INCLUDING DOCUMENTS INCORPORATED OR DEEMED INCORPORATED BY REFERENCE TO
THE EXTENT REQUESTED BY SUCH PERSON), WHICH DOCUMENTS WILL BE SUBJECT TO THE
REVIEW OF SUCH INVESTORS WITHIN SUCH FIVE BUSINESS DAYS. THE COMPANY SHALL NOT
FILE THE REGISTRATION STATEMENT OR ANY SUCH PROSPECTUS OR ANY AMENDMENTS OR
SUPPLEMENTS THERETO TO WHICH THE HOLDERS OF A MAJORITY OF THE REGISTRABLE SHARES
SHALL REASONABLY OBJECT IN GOOD FAITH BASED ON THE ADVICE OF COUNSEL AND THE
COMPANY SHALL MAKE REASONABLE EFFORTS TO ADDRESS THE OBJECTIONS RAISED.  IN THE
EVENT THE HOLDERS OF A MAJORITY OF THE REGISTRABLE SHARES OBJECT TO ANY SUCH
FILING PURSUANT TO THE PREVIOUS SENTENCE, THEN THE REQUIRED FILING DATE OR
EFFECTIVENESS DATE, AS THE CASE MAY BE, SHALL BE EXTENDED BY THE NUMBER OF DAYS
THAT ELAPSE BETWEEN THE DATE THE COMPANY IS NOTIFIED OF THE OBJECTION UNTIL THE
DAY FOLLOWING THE DATE THE COMPANY HAS BEEN NOTIFIED THAT SUCH OBJECTION NO
LONGER EXISTS.

(b)           Following the effective date of the Registration Statement under
Section 5.2, the Company shall, upon the request of the Investors, forthwith
supply such reasonable number of copies of the Registration Statement,
preliminary prospectus and prospectus meeting the requirements of the Securities
Act, and other documents necessary or incidental to the public offering of the
Registrable Shares, as shall be reasonably requested by the Investors to permit
the Investors to make a public distribution of the Registrable Shares registered
in connection with the Registration Statement.

(c)           The Company shall prepare and file with the SEC such amendments
and supplements to such Registration Statement and the prospectus used in
connection with such Registration Statement as may be necessary to comply with
the Securities Act with respect to the disposition of all Shares covered by such
Registration Statement during the period of time such Registration Statement
remains effective;

(d)           The Company shall use its commercially reasonable efforts to
register and qualify the Shares covered by such Registration Statement under
such other securities or Blue Sky laws of such jurisdictions as shall be
reasonably requested by the Investors; provided that the Company shall not be
required in connection therewith or as a condition thereto to qualify to do
business or to file a general consent to service of process in any such states
or jurisdictions;

(e)           During the period of time such Registration Statement remains
effective, the Company shall notify each Investor of Registrable Shares covered
by such registration statement at any time when a prospectus relating thereto is
required to be delivered under the Securities Act or the happening of any event
as a result of which the prospectus included in such Registration Statement, as
then in effect, includes an untrue statement of a material fact or omits to
state a material fact required to be stated therein or necessary to make the
statements therein not misleading in the light of the circumstances then
existing;

13

--------------------------------------------------------------------------------

(f)            The Company shall use its commercially reasonable efforts to
cause all such Registrable Shares registered hereunder to be listed on each
securities exchange on which securities of the same class issued by the Company
are then listed;

(g)           The Company shall provide a transfer agent and registrar for all
Registrable Shares registered hereunder and a CUSIP number for all such
Registrable Shares, in each case not later than the effective date of such
registration; and

(k)           The obligations of the Company hereunder with respect to the
Registrable Shares are subject to the Investors’ furnishing to the Company such
information concerning the Investors, the Registrable Shares and the terms of
the Investors’ offering of such Registrable Shares as are required to be
included in the Registration Statement by Commission regulations or pursuant to
a specific Commission comment on the Registration Statement.

5.4           Expenses.  All expenses incurred in effecting a registration
pursuant to this Agreement (including, without limitation, all registration,
qualification and filing fees, printing expenses, fees and disbursements of
counsel for the Company, blue sky fees and expenses) shall be borne by the
Company.  All transfer taxes, underwriting discounts and selling commissions
applicable to the sale of the Registrable Shares shall be borne by the Investors
thereof.

5.5           Indemnification.  In the event any Registrable Shares are included
in a Registration Statement under this Section 5:

(a)           To the extent permitted by law, the Company will indemnify and
hold harmless each Investor, the partners, officers, directors, stockholders,
members and managers of such Investor, each person, if any, who controls such
Investor within the meaning of the Securities Act or the Exchange Act, against
any losses, claims, damages, or liabilities (joint or several) to which they may
become subject under the Securities Act, the Exchange Act or other federal or
state law, insofar as such losses, claims, damages, or liabilities (or actions
in respect thereof) arise out of or are based upon any of the following
statements, omissions or violations (each, a “Violation”): (i) any untrue
statement or alleged untrue statement of a material fact contained in such
Registration Statement, including any preliminary prospectus or final prospectus
contained therein or any amendments or supplements thereto, (ii) the omission or
alleged omission to state therein a material fact required to be stated therein,
or necessary to make the statements therein not misleading, or (iii) any
violation or alleged violation by the Company of the Securities Act, the
Exchange Act, any state securities law or any rule or regulation promulgated
under the Securities Act, the Exchange Act or any state securities law; and the
Company will pay to each such Investor, underwriter or controlling person, as
incurred, any legal or other expenses reasonably incurred by them in connection
with investigating or defending any such loss, claim, damage, liability, or
action; provided, however, that the indemnity agreement contained in this
Section 5.5(a) shall not apply to amounts paid in settlement of any such loss,
claim, damage, liability, or action if such settlement is effected without the
consent of the Company (which consent shall not be unreasonably withheld or
delayed), nor shall the Company be liable to any Investor, underwriter or
controlling person for any such loss, claim, damage, liability, or action to the
extent that it arises out of or is based upon a Violation which occurs in
reliance upon and in conformity with written information furnished

14

--------------------------------------------------------------------------------

expressly for use in connection with such registration by any such Investor,
underwriter or controlling person.

(b)           To the extent permitted by law, each selling Investor will
indemnify and hold harmless the Company, each of its directors, each of its
officers who has signed the Registration Statement, each person, if any, who
controls the Company within the meaning of the Securities Act, against any
losses, claims, damages, or liabilities (joint or several) to which any of the
foregoing persons may become subject, under the Securities Act, the Exchange Act
or other federal or state law, insofar as such losses, claims, damages, or
liabilities (or actions in respect thereto) arise out of or are based upon any
Violation, in each case to the extent (and only to the extent) that such
Violation occurs in reliance upon and in conformity with written information
furnished by such Investor expressly for use in connection with such
registration; and each such Investor will pay, as incurred, any legal or other
expenses reasonably incurred by any person indemnified pursuant to this Section
5.5(b), in connection with investigating or defending any such loss, claim,
damage, liability, or action; provided, however, that the indemnity agreement
contained in this Section 5.5(b) shall not apply to amounts paid in settlement
of any such loss, claim, damage, liability or action if such settlement is
effected without the consent of the Investor (which consent shall not be
unreasonably withheld or delayed); provided further that in no event shall any
indemnity under this Section 5.5(b) exceed the net proceeds from the offering
received by such Investor.

(c)           Promptly after receipt by an indemnified party under this Section
5.5 of notice of the commencement of any action (including any governmental
action), such indemnified party will, if a claim in respect thereof is to be
made against any indemnifying party under this Section 5.5, deliver to the
indemnifying party a written notice of the commencement thereof and the
indemnifying party shall have the right to participate in, and, to the extent
the indemnifying party so desires, jointly with any other indemnifying party
similarly noticed, to assume the defense thereof with counsel mutually
satisfactory to the parties; provided, however, that an indemnified party
(together with all other indemnified parties which may be represented without
conflict by one counsel) shall have the right to retain one separate counsel,
with the reasonable fees and expenses to be paid by the indemnifying party, if
representation of such indemnified party by the counsel retained by the
indemnifying party would be inappropriate due to actual or potential differing
interests between such indemnified party and any other party represented by such
counsel in such proceeding. The failure to deliver written notice to the
indemnifying party within a reasonable time after receipt of notice of the
commencement of any such action, if prejudicial to its ability to defend such
action, shall relieve such indemnifying party of any liability to the
indemnified party under this Section 5.5, but the omission so to deliver written
notice to the indemnifying party will not relieve it of any liability that it
may have to any indemnified party otherwise than under this Section 5.5.

(d)           If the indemnification provided for in this Section 5.5 is held by
a court of competent jurisdiction to be unavailable to an indemnified party with
respect to any loss, liability, claim, damage or expense referred to therein,
then the indemnifying party, in lieu of indemnifying such indemnified party
hereunder, shall contribute to the amount paid or payable by such indemnified
party as a result of such loss, liability, claim, damage, or expense in such
proportion as is appropriate to reflect the relative fault of the indemnifying
party on the one hand and of the indemnified party on the other in connection
with the statements or omissions that

15

--------------------------------------------------------------------------------

resulted in such loss, liability, claim, damage or expense as well as any other
relevant equitable considerations; provided that in no event shall any
contribution by an Investor under this Section 5.5(d) exceed the net proceeds
from the offering received by such Investor.  The relative fault of the
indemnifying party and of the indemnified party shall be determined by reference
to, among other things, whether the untrue or alleged untrue statement of a
material fact or the omission to state a material fact relates to information
supplied by the indemnifying party or by the indemnified party and the parties’
relative intent, knowledge, access to information, and opportunity to correct or
prevent such statement or omission.

(e)           Notwithstanding the foregoing, to the extent that the provisions
on indemnification and contribution contained in the underwriting agreement
entered into in connection with the underwritten public offering are in conflict
with the foregoing provisions, the provisions in the underwriting agreement
shall control.

(f)            The obligations of the Company and Investors under this Section
5.5 shall survive the completion of any offering of Registrable Shares in a
registration statement and the termination of this Agreement.

5.6           Suspension of Sales.

(a)           With respect to the Registration Statement filed pursuant to
Section 5.2, subject to the payment of any liquidated damages which may accrue
pursuant to Section 5.2(b)(iv), the Company may suspend sales of Registrable
Shares under such Registration Statement for a period of not more than
seventy-five (75) days in any twelve (12) month period with respect to such
Registration Statement if, at any time the Company is engaged in confidential
negotiations or other confidential business activities, the disclosure of which
would be required if such sales were not suspended and the Board of Directors of
the Company determines in good faith that such suspension would be in the
Company’s best interest at such time; provided, that the Company shall not be
permitted to suspend such sales for more than seventy-five (75) days in any
twelve (12) month period.  In order to suspend sales pursuant to this Section
5.6(a), the Company shall promptly (but in any event within five (5) business
days), upon determining to seek such suspension, deliver to each holder of
Registrable Shares a certificate signed by an executive officer of the Company
stating that the Company is suspending such filing pursuant to this Section
5.6(a). Each holder of Registrable Shares hereby agrees to keep confidential any
information disclosed to it in any such certificate (including the fact that a
certificate was delivered).

(b)           If the Company suspends such Registration Statement pursuant to
Section 5.6(a) above, the Company shall, as promptly as practicable following
the termination of the circumstances which entitled the Company to do so but in
no event more than fifteen (15) days thereafter, take such actions as may be
necessary to file or reinstate the effectiveness of such Registration Statement
and/or give written notice to the selling Investors authorizing them to resume
sales pursuant to such Registration Statement.  If, as a result thereof, the
prospectus included in such Registration Statement has been amended to comply
with the requirements of the Securities Act, the Company shall enclose such
revised prospectus with the notice to the selling Investors given pursuant to
this Section 5.6(b), and the selling Investors shall make no

16

--------------------------------------------------------------------------------

offers or sales of Shares pursuant to such Registration Statement other than by
means of such revised prospectus.

5.7           Transfer or Assignment of Registration Rights.  The rights to
cause the Company to register Registrable Shares granted to an Investor by the
Company under this Section 5 may be transferred or assigned by an Investor to a
transferee or assignee of such Registrable Shares that (i) is a subsidiary,
parent, current or former partner, current or former limited partner, current or
former member, current or former manager or stockholder of an Investor, (ii) is
an entity controlling, controlled by or under common control, or under common
investment management, with an Investor, including without limitation a
corporation, partnership or limited liability company that is a direct or
indirect parent or subsidiary of the Investor, or (iii) is a transferee or
assignee of not less than 50,000 shares of Registrable Shares (as presently
constituted and subject to subsequent adjustments for stock splits, stock
dividends, reverse stock splits and the like), provided that the Company is
given written notice at the time of or within a reasonable time after said
transfer or assignment, stating the name and address of said transferee or
assignee and identifying the Securities with respect to which such registration
rights are being transferred or assigned, and provided further that the
transferee or assignee of such rights assumes the obligations of such Investor
under this Section 5.

5.8           Reports Under Exchange Act.  With a view to making available to
the Investors the benefits of Rule 144 promulgated under the Securities Act and
any other rule or regulation of the SEC that may at any time permit an Investor
to sell Securities of the Company to the public without registration, the
Company agrees to:

(a)           Make and keep public information available, as those terms are
used in SEC Rule 144, at all times;

(b)           File with the SEC in a timely manner all reports and other
documents required of the Company under the Securities Act and the Exchange Act;

(c)           Furnish to any Investor, so long as the Investor owns any
Registrable Shares, forthwith on request, (i) a written statement by the Company
that it has complied with the reporting requirements of SEC Rule 144, the
Securities Act and the Exchange Act, (ii) a copy of the most recent annual or
quarterly report of the Company and such other reports and documents so filed by
the Company, and (iii) such other information as may be reasonably requested in
availing any Investor of any rule or regulation of the SEC that permits the
selling of any such securities without registration; and

(d)           Undertake any additional actions reasonably necessary to maintain
the availability of the use of Rule 144.

5.9           Delay of Registration.  No Investor shall have any right to obtain
or seek an injunction restraining or otherwise delaying any registration as the
result of any controversy that might arise with respect to the interpretation or
implementation of this Section 5.

17

--------------------------------------------------------------------------------

6.             CONDITIONS TO INVESTOR OBLIGATIONS AT CLOSING.

THE OBLIGATIONS OF THE INVESTORS TO PURCHASE THE SECURITIES AT THE CLOSING ARE
SUBJECT TO THE FULFILLMENT ON OR PRIOR TO THE CLOSING OF EACH OF THE FOLLOWING
CONDITIONS:

6.1           Representations and Warranties.  The representations and
warranties of the Company contained in Section 2 shall be true in all material
respects on and as of the Closing Date with the same effect as though such
representations and warranties had been made on and as of the Closing Date,
except that any representations and warranties stated as being true and correct
as of a date other than the date hereof shall be true and correct as of such
other date.

6.2           Performance.  The Company shall have performed and complied with
all agreements, obligations and conditions contained in this Agreement that are
required to be performed or complied with by it on or before the Closing.

6.3           Qualifications.  All authorizations, approvals, or permits, if
any, of any governmental authority or regulatory body of the United States or of
any state of the United States that are required in connection with the lawful
issuance and sale of the Securities to the Investors pursuant to this Agreement
shall have been duly obtained and shall be effective on and as of the Closing.

6.4           Proceedings and Documents.  All corporate and other proceedings
undertaken in connection with the transactions contemplated at the Closing and
all documents incident thereto shall be reasonably satisfactory in form and
substance to each Investor, and they shall have received all such counterpart
original and certified or other copies of such documents as they may reasonably
request.

6.5           Absence of Litigation.  No proceeding challenging this Agreement
or the transactions contemplated hereby or thereby, or seeking to prohibit,
alter, prevent or delay the Closing, shall have been instituted against the
Company before any court, arbitrator or governmental body, agency or official
and shall be pending.

6.6           Compliance Certificate.  The Company shall deliver to the
Investors at the Closing, relating to the Investors’ purchase of Securities, a
certificate signed by the Chief Executive Officer of the Company stating that
the Company has complied with or satisfied each of the conditions to the
Investors’ obligation to consummate the Closing set forth in Sections 6.1
through 6.5, unless waived in writing by the Investors.

6.7           Legal Prohibition.  The purchase of the Securities by the
Investors shall not be prohibited by any law or governmental order or
regulation.

7.             CONDITIONS TO THE COMPANY’S OBLIGATIONS AT CLOSING.

The obligations of the Company under Section 1 of this Agreement are subject to
the fulfillment on or before the Closing of each of the following conditions:

7.1           Representations and Warranties.  The representations and
warranties of each Investor contained in Section 3 shall be true in all respects
on and as of the Closing Date

18

--------------------------------------------------------------------------------

with the same effect as though such representations and warranties had been made
on and as of the Closing Date, except that any representations and warranties
stated as being true and correct as of a date other than the date hereof shall
be true and correct as of such other date.

7.2           Performance.  Each Investor shall have performed and complied with
all agreements, obligations and conditions contained in this Agreement that are
required to be performed or complied with by it on or before the Closing.

7.3           Qualifications.  All authorizations, approvals, or permits, if
any, of any governmental authority or regulatory body of the United States or of
any state of the United States that are required in connection with the lawful
issuance and sale of the Securities to the Investors pursuant to this Agreement
shall have been duly obtained and shall be effective on and as of the Closing.

7.4           Proceedings and Documents.  All corporate and other proceedings
undertaken in connection with the transactions contemplated by this Agreement
and all documents incident thereto shall be reasonably satisfactory in form and
substance to the Company and its counsel, and they shall have received all such
counterpart original and certified or other copies of such documents as they may
reasonably request.

8.             MISCELLANEOUS.

8.1           Survival of Warranties.  The warranties, representations,
agreements, covenants and undertakings of the Company or the Investors contained
in or made pursuant to this Agreement shall survive the execution and delivery
of this Agreement and the Closing and shall in no way be affected by any
investigation of the subject matter thereof made by or on behalf of the
Investors or the Company.

8.2           Incorporation by Reference.  All Exhibits and Schedules appended
to this Agreement are herein incorporated by reference and made a part hereof.

8.3           Successor and Assignees.  All terms, covenants, agreements,
representations, warranties and undertakings in this Agreement made by and on
behalf of any of the parties hereto shall bind and inure to the benefit of the
respective successors and assigns of the parties hereto (including transferees
of any Securities) whether so expressed or not, subject to Section 5.7.

8.4           Amendments and Waivers.  Neither this Agreement nor any provision
hereof shall be waived, modified, changed, discharged, terminated, revoked or
canceled except by an instrument in writing signed by the Company and the
Holders of at least 75% of the then outstanding Registrable Securities.  Failure
of either party to exercise any right or remedy under this Agreement or any
other agreement between the Company and the Investors, or otherwise, or delay by
the Company or the Investors in exercising such right or remedy, will not
operate as a waiver thereof, nor shall any single or partial exercise thereof
preclude any other or further exercise thereof or the exercise of any other
right, power or privilege.  The rights and remedies herein provided shall be
cumulative and not exclusive of any rights or remedies provided by law.

19

--------------------------------------------------------------------------------

8.5           Governing Law.  This Agreement shall be deemed a contract made
under the laws of the State of New York, without giving effect to the conflicts
of law principles thereof.

8.6           Notices.  All notices, requests, consents, demands, notice or
other communication required or permitted under this Agreement shall be in
writing and shall be deemed duly given and received when delivered personally or
transmitted by facsimile, or one business day after being deposited for next-day
delivery with a nationally recognized overnight delivery service, or three days
after being deposited as first class mail with the United States Postal
Services, all charges or postage prepaid, and properly addressed:

to the Company at:

FermaVir Pharmaceuticals, Inc.

420 Lexington Avenue, Suite 445

New York, New York 10170

Tel:  (212) 413-0802

Fax:  (646) 723-2744

Attention:  Chief Executive Officer

with a copy (which shall not constitute notice) to:

Sichenzia Ross Friedman Ference LLP

1065 Avenue of the Americas

New York, New York 10018

Fax: (212) 930-9725

Attention: Jeffrey J. Fessler

or to the Investors at the address set forth opposite each Investor’s name on
Exhibit A hereto

or such other address as may be furnished in writing by a party hereto.

8.7           Counterparts. This Agreement may be executed in counterparts, all
of which together shall constitute one and the same instrument.

8.8           Effect of Headings.  The section and paragraph headings herein are
included for convenience only and shall not affect the construction hereof.

8.9           Entire Agreement.  This Agreement and the Exhibits and Schedules
hereto and thereto constitute the entire agreement among the Company and the
Investors with respect to the subject matter hereof.  There are no
representations, warranties, covenants or undertakings with respect to the
subject matter hereof other than those expressly set forth herein.  This
Agreement supersedes all prior agreements between the parties with respect to
the Securities purchased hereunder and the subject matter hereof.

8.10         Publicity.  Neither party shall originate any publicity, news
release or other public announcement, written or oral, whether relating to the
performance under this

20

--------------------------------------------------------------------------------

Agreement or the existence of any arrangement between the parties, without the
prior written consent of the other party (which consent shall not be
unreasonably withheld or delayed), except where such publicity, news release or
other public announcement is required by law or by Section 4.1; provided that,
in such event, each such party shall (a) promptly consult the other party in
connection with any such publicity, news release or other public announcement
prior to its release; (b) promptly provide the other party a copy thereof; and
(c) use commercially reasonable efforts to ensure that such portions of such
information as may reasonably be designated by the other party are accorded
confidential treatment by the applicable governmental entity.

8.11         Severability.  If any provision of this Agreement is held by a
court of competent jurisdiction to be unenforceable under applicable law, such
provision shall be replaced with a provision that accomplishes, to the extent
possible, the original business purpose of such provision in a valid and
enforceable manner, and the balance of the Agreement shall be interpreted as if
such provision were so modified and shall be enforceable in accordance with its
terms.

8.12         Interpretation.  This Agreement shall be construed according to its
fair language.  The rule of construction to the effect that any ambiguities are
to be resolved against the drafting party shall not be employed in the
interpretation of this Agreement.

8.13         No Strict Construction.  The language used in this Agreement will
be deemed to be the language chosen by the parties to express their mutual
intent, and no rules of strict construction will be applied against any party.

8.14         Independent Nature of Investors’ Obligations and Rights.  The
obligations of each Investor under this Agreement are several and not joint with
the obligations of any other Investor, and no Investor shall be responsible in
any way for the performance of the obligations of any other Investor under this
Agreement. The decision of each Investor to purchase Securities pursuant to this
Agreement has been made by such Investor independently of any other Investor and
independently of any information, materials, statements or opinions as to the
business, affairs, operations, assets, properties, liabilities, results of
operations, condition (financial or otherwise) or prospects of the Company which
may have been made or given by any other Investor or by any agent or employee of
any other Investor, and no Investor or any of its agents or employees shall have
any liability to any other Investor (or any other person) relating to or arising
from any such information, materials, statements or opinions.  Nothing contained
herein, and no action taken by any Investor pursuant thereto, shall be deemed to
constitute the Investors as a partnership, an association, a joint venture or
any other kind of entity, or create a presumption that the Investors are in any
way acting in concert or as a group with respect to such obligations or the
transactions contemplated by this Agreement. Each Investor acknowledges that no
other Investor has acted as agent for such Investor in connection with making
its investment hereunder and that no other Investor will be acting as agent of
such Investor in connection with monitoring its investment hereunder.  Each
Investor shall be entitled to independently protect and enforce its rights,
including without limitation the rights arising out of this Agreement, and it
shall not be necessary for any other Investor to be joined as an additional
party in any proceeding for such purpose. The Company has elected to provide all
Investors with the same terms and

21

--------------------------------------------------------------------------------

form of this Agreement for the convenience of the Company and not because it was
required or requested to do so by the Investors.

22

--------------------------------------------------------------------------------

IN WITNESS WHEREOF, this Agreement has been executed as of the date first above
written, by the duly authorized representatives of the parties hereto.

FERMAVIR PHARMACEUTICALS, INC.

 

 

 

 

 

 

 

 

 

 

By:

 

 

 

 

 

 

 

Name:

 

 

 

 

 

 

 

Title:

 

 

 

 

 

 

 

 

 

 

 

INVESTOR

 

 

 

 

 

 

 

 

Name of Person or Entity

 

 

 

 

 

By:

 

 

 

 

Name:

 

 

 

Title:

 

 

 

 

 

--------------------------------------------------------------------------------

Exhibit A

Investor Name and
Notice Address

 

Cash
Investment
Amount

 

Number of
Shares

 

Number of
Warrants
(1)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total

 

 

 

 

 

 

 

--------------------------------------------------------------------------------

(1)  A number of warrants as equals 200% of the Shares subscribed for by each
Investor

--------------------------------------------------------------------------------